Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 14/20 | 0.64 |
| ▸ | CPB1 | P15086 | 5/20 | 0.64 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10583023 | 1.00 | CPB2 (0.64) | CPB2CPB1GRIA4KDM5AKDM5B | |
| SCHEMBL6057065 | 0.92 | CPB2 (0.66) | CPB2CPB1GRIA4CYP1A2GRIA1 | |
| SCHEMBL13602099 | 0.90 | CPB2 (0.65) | CPB2CPB1GRIA4CYP1A2 | |
| SCHEMBL7733278 | 0.89 | CPB2 (0.64) | CPB2CPB1GRIA4CYP1A2 | |
| SCHEMBL7741446 | 0.88 | CPB2 (0.61) | CPB2CPB1GRIA4CYP1A2GRIA1 | |
| SCHEMBL8760849 | 0.88 | CPB2 (0.61) | CPB2CPB1GRIA4CYP1A2GRIA1 | |
| SCHEMBL8348975 | 0.85 | CPB2 (0.57) | CPB2CPB1KDM5AKDM5B | |
| Hydrochloric Acid SCHEMBL6333571 | 0.85 | CPB2 (0.51) | CPB2CPB1GRIA4CYP1A2GRIA1 | |
| SCHEMBL10137873 | 0.84 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL7741830 | 0.83 | CPB2 (0.50) | CPB2CPB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | claimed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | claimed |
| US-4560515-A | NON-SYMMETRICAL KETENE REACTED WITH A-HYDROXYNITRILE; TERTUARY AMINE CATALYST | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | claimed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| EP-0109681-A2 | process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | claimed |
| US-20240140935-A1 | NON-COVALENT DIMER CATION, SALT THEREOF, PREPARATION METHOD THEREOF, AND USE THEREOF AS ANTIOXIDANT | SUZHOU PROTONATION CHAIN BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| CN-117820232-A | Non-covalent dimer cations, salts thereof, preparation method thereof and antioxidation application thereof | 苏州质子链生物技术有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6759426-B2 | RESPIRATORY SYSTREM DISORDERS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISORDERS | PFIZER INC | 2004-07-06 | — | — | US | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| EP-0312124-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-19 | — | — | EP | disclosed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | disclosed |
| US-4681947-A | NONSYMMETRICAL KETENE, ALPHA-HYDROXY NITRILE OR ALDEHYDE AND CYANIDE, CYCLO(D-PHENYLALANYL-D-HISTADINE) | E.I. DU PONT DE NEMOURS AND COMPANY | 1987-07-21 | — | — | US | disclosed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
| US-4560515-A | NON-SYMMETRICAL KETENE REACTED WITH A-HYDROXYNITRILE; TERTUARY AMINE CATALYST | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0109681-A2 | process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140935-A1 | NON-COVALENT DIMER CATION, SALT THEREOF, PREPARATION METHOD THEREOF, AND USE THEREOF AS ANTIOXIDANT | SLC10A1, CYP11B1, CYP11B2 | CPB2 1513/4885CPB1 1771/4885GRIA4 1790/4885 |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | CPB2 733/4885CPB1 1085/4885GRIA4 2005/4885 |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | CPB2 733/4885CPB1 1085/4885GRIA4 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.